As we reach the end of May, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI. Excellent finish to make this one of the better weeks for biotech investors this year. We're currently running a 40% OFF ASCO sale, learn more here.
Table 1. BPIQ company weekly/monthly moves and YTD moves
Category | Weekly Move | YTD Move |
|---|---|---|
All BPIQ Companies | +2.96% | -46.47% |
CAR-T Companies | +1.26% | -50.23% |
Gene Editing Companies | +0.31% | -50.99% |
XBI | +3.63% | -36.50% |
See the biggest moves from last week below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week
ASCO
ASCO abstracts and additional data were released as scheduled. See our separate ASCO post on this key annual cancer meeting, including updated info on big stock movers on abstract release.
Biggest positive move
$CBIO +20.4% Catalyst Biosciences Sells Complement Portfolio for $60 Million.
Biggest negative move
$VRCA -63.9% Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC.
Additional big moves
$TIL -24.3% (ASCO) Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
$ACET +31.4% (ASCO) Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
$IOVA -52.7% (ASCO) Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma
$NRIX -22.7% Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development
$SWTX -11.4% (ASCO) SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors.
$NYMX -63.9% NYMOX Receives RTF letter from FDA.
For ASCO abstract release biggest movers see our separate ASCO post
Highlights for next week
To see next week's Big Movers HERE, subscribe. Learn more here.
ASCO abstracts we're released this past week, but next week the conference starts.
See our Separate ASCO post for more details about this key annual cancer biopharma meeting
See our Big Movers post to learn about upcoming Movers throughout June and PDUFAs, after subscribing. Learn more here.